Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate. Revenues…
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
Sanofi SA (NASDAQ:SNY) forecasts 2023 adjusted earnings per share to grow by a “low single-digit” percentage, not considering an expected negative…
Big Tech Calls From Apple, Amazon, Alphabet Paint ‘Different Picture’ Than What Tech Bears Hoped For Says, Wedbush Analyst
Wedbush analyst Dan Ives said Thursday that calls from Apple Inc (NASDAQ: AAPL), Amazon.com, Inc (NASDAQ: AMZN) and Google parent Alphabet Inc (NASDAQ:
Johnson & Johnson’s Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Cantor Fitzgerald is previewing its thoughts on a potential interim analysis for Johnson & Johnson’s (NYSE:JNJ) Phase 3 MARIPOSA study of Rybrevant (amivantamab)…
Eli Lilly Posts Weaker Q4 Sales On Slower Demand For Its COVID-19 Treatment, Overshadowing Annual Guidance
Eli Lilly And Co (NYSE:LLY) has reported Q4 sales of $7.30 billion, down 9% Y/Y, missing the consensus of $7.33…
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
Merck & Co Inc’s (NYSE:MRK) Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the…
Humana Q4 Profits Beat Expectations, Sees Growth Of ‘At Least’ 625,000 Medicare Advantage Members In 2023
Humana Inc (NYSE:HUM) reported Q4 adjusted EPS of $1.62, up from $1.24 a year ago, beating the consensus of $1.46.…
AmerisourceBergen Q1 Earnings Surpass Expectations, Boosts Annual Guidance
AmerisourceBergen Corp’s (NYSE:ABC) Q1 FY23 adjusted EPS reached $2.71, up 5% Y/Y, beating the consensus of $2.63. Revenue of $62.85…
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Amgen Inc’s (NASDAQ:AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and…
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine
GSK Plc (NYSE:GSK) reported an adjusted fourth-quarter profit of 25.8 pence per share on sales of about £7.4 billion, up 4.2%…